Paolo Tarantino: The 5 S rules help memorizing a simple framework to manage ILD
Paolo Tarantino shared on LinkedIn:
“T-DXd is rapidly expanding in indications, from HER2+, to HER2-low, and most recently to HER2-ultralow breast cancer.
At present, most patients with metastatic breast cancer can be considered eligible for the drug.
This calls for a concomitant expansion in our efforts to mitigate its side effects: particularly ILD, which can prove life threatening.
The 5 S rules help memorizing a simple framework to manage ILD:
Screen patients for lung comorbidities, Scan frequently (CT chest every 6-12 weeks), be Synergistic with all the multidisciplinary care team, Suspend T-DXd if ILD is suspected, use Steroids early.”
Additional information.
Source: Paolo Tarantino/LinkedIn
Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023